FRANKFURT, Nov 4 (Reuters) - Boehringer Ingelheim and Eli Lilly (LLY.N), opens new tab said their diabetes drug Jardiance was shown to slow the progression of chronic kidney disease (CKD), as they ...

“Unfortunately, a quarter of people who survive a stroke will have another stroke,” said lead study author Dr. M. Ali Sheffeh. “They are also at risk for other cardiovascular events such as a heart ...

The logo of German pharmaceutical company Boehringer Ingelheim is seen at its building in Shanghai FRANKFURT (Reuters) - Germany's unlisted Boehringer Ingelheim said operating income rose 1.8% in 2021 ...

FRANKFURT, March 29 (Reuters) - German unlisted drugmaker Boehringer Ingelheim said on Wednesday its operating income rose 1.4% in 2022, as more prescriptions of diabetes drug Jardiance trumped higher ...

Jardiance sparked controversy with their commercial starring Deanna Colón that originally aired in April 2023. The ad ...

Besides the diabetes and obesity duo of Mounjaro and Zepbound, the SGLT2 inhibitor Jardiance and the CDK4/6 cancer drug Verzenio were cited as the main growth drivers for Eli Lilly’s first quarter.

Boehringer Ingelheim and Eli Lilly And Co (NYSE: LLY) said their diabetes drug Jardiance showed to slow the progression of chronic kidney disease. The companies said the EMPA-KIDNEY phase 3 trial met ...

Intended to help with Type 2 diabetes, Ozempic is often used by those looking to lose weight -- perhaps because of its name recognition. YouTube If you’ve ever found yourself absentmindedly humming ...

Some health-obsessed Americans believe the next antiaging therapeutic already exists—in the medicine cabinets of millions of diabetes patients. The widely used class of drugs, called SGLT2 inhibitors ...